Suivre
Xavier Duportet
Xavier Duportet
Affiliation inconnue
Adresse e-mail validée de eligo-bioscience.com
Titre
Citée par
Citée par
Année
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
D Bikard, CW Euler, W Jiang, PM Nussenzweig, GW Goldberg, X Duportet, ...
Nature biotechnology 32 (11), 1146-1150, 2014
9112014
A platform for rapid prototyping of synthetic gene networks in mammalian cells
X Duportet, L Wroblewska, P Guye, Y Li, J Eyquem, J Rieders, T Rimchala, ...
Nucleic acids research 42 (21), 13440-13451, 2014
1502014
The biological interpretation of metabolomic data can be misled by the extraction method used
X Duportet, RBM Aggio, S Carneiro, SG Villas-Bôas
Metabolomics 8, 410-421, 2012
1242012
Rapid, modular and reliable construction of complex mammalian gene circuits
P Guye, Y Li, L Wroblewska, X Duportet, R Weiss
Nucleic acids research 41 (16), e156-e156, 2013
1052013
Improving sequence-specific antimicrobials by blocking dna repair
D Bikard, CUI Lun, X Duportet, JF Rodriguez
942017
Development of sequence-specific antimicrobials based on programmable CRISPR-Cas nucleases
D Bikard, C Euler, W Jiang, PM Nussenzweig, GW Goldberg, X Duportet, ...
Nature biotechnology 32 (11), 1146, 2014
632014
Comparison of integrases identifies Bxb1-GA mutant as the most efficient site-specific integrase system in mammalian cells
B Jusiak, K Jagtap, L Gaidukov, X Duportet, K Bandara, J Chu, L Zhang, ...
ACS Synthetic Biology 8 (1), 16-24, 2019
372019
Design and connection of robust genetic circuits
A Randall, P Guye, S Gupta, X Duportet, R Weiss
Methods in enzymology 497, 159-186, 2011
342011
Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
X Duportet, A Decrulle, C del Carmen Gil-Cruz, CI Pérez-Shibayama, ...
US Patent 11,376,286, 2022
62022
In situ targeted mutagenesis of gut bacteria
AK Brödel, L Charpenay, M Galtier, FJ Fuche, R Terrasse, C Poquet, ...
bioRxiv, 2022.09. 30.509847, 2022
42022
Voices of biotech leaders
AE Abong, K Bosley, C Casebourn, P Chan, J Chen, M Chen, G Church, ...
Nature Biotechnology 39 (6), 654-660, 2021
42021
Optimized vector for delivery in microbial populations
A Decrulle, JF Rodriguez, X Duportet, D Bikard
US Patent 10,808,254, 2020
42020
Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
X Duportet, A Decrulle, C del Carmen Gil-Cruz, CI Pérez-Shibayama, ...
US Patent 11,224,621, 2022
32022
Developing new tools and platforms for mammalian synthetic biology: From the assembly and chromosomal integration of complex DNA circuits to the engineering of artificial …
X Duportet
Université Paris Diderot (Paris 7), 2014
32014
Optimized vector for delivery in microbial populations
A Decrulle, JF Rodriguez, X Duportet, D Bikard
US Patent 11,905,516, 2024
22024
Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
X Duportet, A Decrulle, C del Carmen Gil-Cruz, CI Pérez-Shibayama, ...
US Patent 11,534,467, 2022
22022
Recombinases and target sequences
R Weiss, XC Duportet, G Batt, Y Li
US Patent 10,731,153, 2020
22020
Method for killing bacteria with an engineered postbiotic
A Decrulle, X Duportet
US Patent 11,541,106, 2023
12023
Optimized vector for delivery in microbial populations
A Decrulle, JF Rodriguez, X Duportet, D Bikard
US Patent App. 17/356,079, 2021
12021
Optimized vector for delivery in microbial populations
A Decrulle, JF Rodriguez, X Duportet, D Bikard
US Patent 11,078,490, 2021
12021
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20